Mechanism of rapid elimination of lysophosphatidic acid and related lipids from the circulation of mice

Abdel Salous, Manikandan Panchatcharam, Manjula Sunkara, Paul Müeller, Anping Dong, Yuhuan Wang, Gregory A. Graf, Susan S. Smyth, Andrew J. Morris

Journal of Lipid Research · 2013 · 85 citations · 31 references

DOIFull text

Open access

Concepts

Abstract

Lysophosphatidic acid (LPA) is a bioactive lipid mediator. Concentrations of the major LPA species in mouse plasma decreased uniformly following administration of a potent selective inhibitor of the LPA-generating lysophospholipase D autotaxin, identifying an active mechanism for removal of LPA from the circulation. LPA, akylglycerol phosphate (AGP), sphingosine 1-phosphate (S1P), and a variety of structural mimetics of these lipids, including phosphatase-resistant phosphonate analogs of LPA, were rapidly eliminated (t1/2 < 30 s) from the circulation of mice following intravenous administration of a single bolus dose without significant metabolism in situ in the blood. These lipids accumulated in the liver. Elimination of intravenously administered LPA was blunted by ligation of the hepatic circulation, and ~90% of LPA administered through the portal vein was accumulated by the isolated perfused mouse liver at first pass. At early times following intravenous administration, more LPA was associated with a nonparenchymal liver cell fraction than with hepatocytes. Primary cultures of nonparenchymal liver cells rapidly assimilated exogenously provided LPA. Our results identify hepatic uptake as an important determinant of the bioavailability of LPA and bioactive lysophospholipid mimetics and suggest a mechanism to explain changes in circulating LPA levels that have been associated with liver dysfunction in humans. Lysophosphatidic acid (LPA) is a bioactive lipid mediator. Concentrations of the major LPA species in mouse plasma decreased uniformly following administration of a potent selective inhibitor of the LPA-generating lysophospholipase D autotaxin, identifying an active mechanism for removal of LPA from the circulation. LPA, akylglycerol phosphate (AGP), sphingosine 1-phosphate (S1P), and a variety of structural mimetics of these lipids, including phosphatase-resistant phosphonate analogs of LPA, were rapidly eliminated (t1/2 < 30 s) from the circulation of mice following intravenous administration of a single bolus dose without significant metabolism in situ in the blood. These lipids accumulated in the liver. Elimination of intravenously administered LPA was blunted by ligation of the hepatic circulation, and ~90% of LPA administered through the portal vein was accumulated by the isolated perfused mouse liver at first pass. At early times following intravenous administration, more LPA was associated with a nonparenchymal liver cell fraction than with hepatocytes. Primary cultures of nonparenchymal liver cells rapidly assimilated exogenously provided LPA. Our results identify hepatic uptake as an important determinant of the bioavailability of LPA and bioactive lysophospholipid mimetics and suggest a mechanism to explain changes in circulating LPA levels that have been associated with liver dysfunction in humans. Lysophosphatidic acid (LPA) denotes a family of radyl hydrocarbon-substituted derivatives of glycerol 3-phosphate. Structural diversity in LPA species identified in biological systems encompasses species with both ester and ether linkages [(the latter of which are collectively termed alkyl glycerol phosphates (AGP)] as well as differences in hydrocarbon chain length and saturation (1Tigyi G. New trends in lysophospholipid research.Biochim. Biophys. Acta. 2013; 1831: 1Crossref PubMed Scopus (7) Google Scholar). LPAs exhibit a broad range of biological activities that are initiated by LPA selective G-protein-coupled cell-surface receptors. Some LPA responses may also be mediated by the nuclear peroxisome proliferator γ receptor and the receptor for advanced glycan end products (2Morris A.J. Smyth S.S. Lysophosphatidic acid and cardiovascular disease: seeing is believing.J. Lipid Res. 2013; 54: 1153-1155Abstract Full Text Full Text PDF PubMed Scopus (7) Google Scholar). LPA is present in blood plasma (3Morris A.J. Selim S. Salous A. Smyth S.S. Blood relatives: dynamic regulation of bioactive lysophosphatidic acid and sphingosine-1-phosphate metabolism in the circulation.Trends Cardiovasc. Med. 2009; 19: 135-140Crossref PubMed Scopus (23) Google Scholar) and accumulates in human atheromas and in experimentally induced atherosclerotic lesions in mice (4Haseruck N. Erl W. Pandey D. Tigyi G. Ohlmann P. Ravanat C. Gachet C. Siess W. The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: involvement of P2Y1 and P2Y12 receptors.Blood. 2004; 103: 2585-2592Crossref PubMed Scopus (106) Google Scholar). Studies using LPA receptor-deficient mice and LPA-directed small molecule therapeutics identify roles for LPA signaling in atherothrombosis and vascular injury responses (5Panchatcharam M. Miriyala S. Yang F. Rojas M. End C. Vallant C. Dong A. Lynch K. Chun J. Morris A.J. et al.Lysophosphatidic acid receptors 1 and 2 play roles in regulation of vascular injury responses but not blood pressure.Circ. Res. 2008; 103: 662-670Crossref PubMed Scopus (75) Google Scholar, 6Panchatcharam M. Miriyala S. Salous A. Wheeler J. Dong A. Mueller P. Sunkara M. Escalante-Alcalde D. Morris A.J. Smyth S.S. Lipid phosphate phosphatase 3 negatively regulates smooth muscle cell phenotypic modulation to limit intimal hyperplasia.Arterioscler. Thromb. Vasc. Biol. 2013; 33: 52-59Crossref PubMed Scopus (39) Google Scholar, 7Cheng Y. Makarova N. Tsukahara R. Guo H. Shuyu E. Farrar P. Balazs L. Zhang C. Tigyi G. Lysophosphatidic acid-induced arterial wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR.Cell. Signal. 2009; 21: 1874-1884Crossref PubMed Scopus (37) Google Scholar). A common variant in the PPAP2B gene encoding the LPA inactivating cell surface integral membrane enzyme lipid phosphate phosphatase 3 (LPP3) may predict LPP3 mRNA expression in blood cells and is strongly associated with increased human cardiovascular disease risk. In mice, PPAP2B expression in vascular smooth muscle cells is protective against vascular injury responses (6Panchatcharam M. Miriyala S. Salous A. Wheeler J. Dong A. Mueller P. Sunkara M. Escalante-Alcalde D. Morris A.J. Smyth S.S. Lipid phosphate phosphatase 3 negatively regulates smooth muscle cell phenotypic modulation to limit intimal hyperplasia.Arterioscler. Thromb. Vasc. Biol. 2013; 33: 52-59Crossref PubMed Scopus (39) Google Scholar, 8Mehta N.N. A genome-wide association study in Europeans and South Asians identifies 5 new loci for coronary artery disease.Circ Cardiovasc Genet. 2011; 4: 465-466Crossref PubMed Scopus (16) Google Scholar). Together, these studies point to an important role for LPA in human cardiovascular disease and focus attention on the need to understand mechanisms regulating bioavailability of this lipid in vascular cells and tissues. LPA is present in human and rodent blood plasma at levels that are generally agreed to be excess of 100 nM where it is generated by hydrolysis of circulating lysophospholipids catalyzed by the secreted lysophospholipase D autotaxin (ATX) (9Umezu-Goto M. Kishi Y. Taira A. Hama K. Dohmae N. Takio K. Yamori T. Mills G.B. Inoue K. Aoki J. et al.Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production.J. Cell Biol. 2002; 158: 227-233Crossref PubMed Scopus (793) Google Scholar). Genetic or pharmacological manipulation of ATX expression and activity establish a close correlation between plasma LPA levels and ATX activity (10Tanaka M. Okudaira S. Kishi Y. Ohkawa R. Iseki S. Ota M. Noji S. Yatomi Y. Aoki J. Arai H. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid.J. Biol. Chem. 2006; 281: 25822-25830Abstract Full Text Full Text PDF PubMed Scopus (385) Google Scholar). Several highly potent and specific small molecule ATX inhibitors produce rapid and substantial decreases in plasma levels of particular LPA species in rodents (11Albers H.M. Dong A. van Meeteren L.A. Egan D.A. Sunkara M. van Tilburg E.W. Schuurman K. van Tellingen O. Morris A.J. Smyth S.S. et al.Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation.Proc. Natl. Acad. Sci. USA. 2010; 107: 7257-7262Crossref PubMed Scopus (166) Google Scholar, J. A. K. E. L. T. A. M. O. S. et autotaxin inhibitor lysophosphatidic acid levels in plasma and the of 2010; PubMed Scopus Google Scholar). These and of of intravenously administered LPA and the bioactive lipid sphingosine 1-phosphate from the circulation of mice and following intravenous administration A. C. Lynch Lipid phosphate 1 lysophosphatidic acid in J. 2009; PubMed Scopus Google Scholar, K. J. S. Y. C. T. as a of plasma sphingosine Res. 2008; PubMed Scopus Google Scholar) that active mechanisms for in situ in blood or of these lipids from the circulation of these mechanisms be of to of the role of LPA and in vascular and and the of bioactive lysophospholipid mimetics as pharmacological of LPA and metabolism and LPA and are in plasma but be in whole blood through mechanisms that LPP3 and cell surface lipid A. C. Lynch Lipid phosphate 1 lysophosphatidic acid in J. 2009; PubMed Scopus Google Scholar, K. J. S. Y. C. T. as a of plasma sphingosine Res. 2008; PubMed Scopus Google Scholar). LPA in whole blood and of exogenously provided LPA from the circulation of mice was in with a in A. C. Lynch Lipid phosphate 1 lysophosphatidic acid in J. 2009; PubMed Scopus Google the of or mechanisms for or of LPA from the circulation is not using to and LPA species in human blood. these to mechanisms for of LPA from the circulation of that the mechanism for of exogenously LPA rapid uptake in the liver and is of in situ or in circulating blood were from and were from The phosphonate analogs of LPA were from of was from Lynch of were from and to and were by the and at the of were from and by and at a of 100 in 5 and were using A was in the and the was using to the of the lipid was the vein using an and the was at the end of the Blood was at times of the whole blood was in and at for in an The cell and were to in for lipid or for of as liver was as N. K. G. M. in J. 2010; PubMed Scopus Google Scholar). were with The liver was perfused at a of 3 the portal vein with and 5 The was with and the liver was at A bolus of as was in the and the was 30 for to 5 and were for of as mice were with a bolus of or in the A was as of isolated liver Cell Biol. PubMed Scopus Google Scholar). the liver was first perfused with and and with and was with as The cells were at for 3 at The was times with The nonparenchymal cells in the and were by at for at of nonparenchymal cell cell isolated as were in and a of as by H. P. of by liver Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). were and with The were with and with the cells for with and cells were by cells and cells and were isolated as and in a were in with with acid at a of for with were on with and for lipid as The of these cell was to be than in with of isolated liver Cell Biol. PubMed Scopus Google Scholar). were from of or which was to a 5 100 2 1 and were for 5 1 and of were and were for 5 at the was to a and were in 100 and in at for was using at were with and to were by using on In for were by and were to or from (11Albers H.M. Dong A. van Meeteren L.A. Egan D.A. Sunkara M. van Tilburg E.W. Schuurman K. van Tellingen O. Morris A.J. Smyth S.S. et al.Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation.Proc. Natl. Acad. Sci. USA. 2010; 107: 7257-7262Crossref PubMed Scopus (166) Google Scholar, L. H. Mueller T. S. J. Sunkara M. H. H.M. et al.Autotaxin and lysophosphatidic acid and in PubMed Scopus Google Scholar, J. S. E. T. H.M. van Meeteren L.A. A.J. van L. et of and by Biol. 2011; PubMed Scopus Google Scholar, T. Sunkara M. Morris A.J. Smyth S.S. of autotaxin to lysophosphatidic acid to and Biol. Chem. 2011; Full Text Full Text PDF PubMed Scopus (106) Google Scholar, S. Sunkara M. Salous A. R. Morris A.J. Smyth S.S. levels of sphingosine 1-phosphate are strongly with but by blood cell Sci. 2011; PubMed Scopus Google Scholar). The was in to the following and In lipids were the to and the lipids of and were by to generated by a range of of the lipids of to an or The lipid for these were by or levels of the in the were using these with for the was also by using an and the following also a to for LPA and species in biological The to LPA and species for these has been Y. Sunkara M. Morris A.J. Lynch of alkyl lysophosphatidic acid by Biophys. Res. PubMed Scopus Google Scholar). were using an Lipid species identified from were for in a to were from these by using and generated using is a that LPAs with and for of the LPA in mouse and human plasma (3Morris A.J. Selim S. Salous A. Smyth S.S. Blood relatives: dynamic regulation of bioactive lysophosphatidic acid and sphingosine-1-phosphate metabolism in the circulation.Trends Cardiovasc. Med. 2009; 19: 135-140Crossref PubMed Scopus (23) Google Scholar). LPA species with radyl are for the which may for as platelet have been in T. S. S. K. Y. A. of lysophosphatidic acid and alkyl in and of biological activities Biophys. Acta. PubMed Scopus Google Scholar) and S. A. K. T. and of lysophosphatidic growth species PubMed Scopus Google but levels in human or mouse plasma have not been to in mouse plasma and to to ATX a using to LPA species with ether and ester which were identified by using a LPA species were identified from the of and alkyl ester LPAs were using LPAs the glycerol which is not in the of which of and and of lipid species were as in using a of human which species at in the range of as by (1Tigyi G. New trends in lysophospholipid research.Biochim. Biophys. Acta. 2013; 1831: 1Crossref PubMed Scopus (7) Google Scholar, A.J. Smyth S.S. Lysophosphatidic acid and cardiovascular disease: seeing is believing.J. Lipid Res. 2013; 54: 1153-1155Abstract Full Text Full Text PDF PubMed Scopus (7) Google Scholar, A.J. Selim S. Salous A. Smyth S.S. Blood relatives: dynamic regulation of bioactive lysophosphatidic acid and sphingosine-1-phosphate metabolism in the circulation.Trends Cardiovasc. Med. 2009; 19: 135-140Crossref PubMed Scopus (23) Google Scholar, H.M. Dong A. van Meeteren L.A. Egan D.A. Sunkara M. van Tilburg E.W. Schuurman K. van Tellingen O. Morris A.J. Smyth S.S. et al.Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation.Proc. Natl. Acad. Sci. USA. 2010; 107: 7257-7262Crossref PubMed Scopus (166) Google Scholar, J. A. K. E. L. T. A. M. O. S. et autotaxin inhibitor lysophosphatidic acid levels in plasma and the of 2010; PubMed Scopus Google Scholar, A. C. Lynch Lipid phosphate 1 lysophosphatidic acid in J. 2009; PubMed Scopus Google LPA species were in plasma from mice on a but were to species at levels the limit of were a single intravenous dose of 30 which is an ATX inhibitor to LPA levels in plasma following administration J. A. K. E. L. T. A. M. O. S. et autotaxin inhibitor lysophosphatidic acid levels in plasma and the of 2010; PubMed Scopus Google Scholar). induced a significant in of the major LPA species administration, that plasma levels of these lipids at by ATX is The of in plasma from was strongly by with the in plasma LPA, that in than in to for the in decreases in plasma LPA levels of in the range in plasma to mouse plasma lipid using not produce significant decreases in plasma LPA that ATX or of on LPA from these not for of decreases in plasma LPA following in not of the of LPA and from the plasma of mice following intravenous of a single bolus dose the of these lipids to be and A. C. Lynch Lipid phosphate 1 lysophosphatidic acid in J. 2009; PubMed Scopus Google Scholar, K. J. S. Y. C. T. as a of plasma sphingosine Res. 2008; PubMed Scopus Google Scholar). of these is by in and rapidly this mice with a single bolus dose of the LPA species in with a plasma that with to and be in plasma using The of plasma by the the of PubMed Scopus Google Scholar) for of plasma LPA for in or intravenous administration, as was in plasma not LPA by was at the point but rapidly the of to in the administered to the of LPA administered intravenously to that the fraction of administered LPA in plasma to the that of the administered LPA was at the point rapid in plasma LPA levels without significant of in blood cells not be by to or a were to of these in mouse plasma or whole blood following intravenous administration of not These results were LPA has been to be in whole blood through mechanisms that have that human and both and phosphatase activity against LPA (6Panchatcharam M. Miriyala S. Salous A. Wheeler J. Dong A. Mueller P. Sunkara M. Escalante-Alcalde D. Morris A.J. Smyth S.S. Lipid phosphate phosphatase 3 negatively regulates smooth muscle cell phenotypic modulation to limit intimal hyperplasia.Arterioscler. Thromb. Vasc. Biol. 2013; 33: 52-59Crossref PubMed Scopus (39) Google Scholar, S.S. Y. Morris A.J. Lipid phosphate lysophosphatidic acid and signaling in studies using inhibitors of lipid phosphate phosphatase Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). the of of LPA in whole mouse blood or plasma levels in these with significant of that a major mechanism was more in plasma the of the a more of an intravenously administered 5 bolus of LPA from the circulation and of a of 1 of LPA in whole blood to the of of LPA from the plasma in mice to the of LPA in whole blood The of of intravenously administered LPA was than the of of LPA in whole blood these results that with LPA be in whole blood through mechanisms that with to products in blood in following intravenous administration of the of of LPA in blood is to for the of of intravenously administered LPA from the the role of in the of intravenously administered LPA from the the of of intravenously administered to that of LPA and that are to G. Y. Y. Tsukahara T. Tsukahara R. J. Tigyi G. phosphonate of lysophosphatidic acid (LPA) and of PubMed Scopus Google Scholar, H. J. Tsukahara R. Y. J. D. Tigyi G. et activity lysophosphatidic acid receptor inhibitor cell in and tumor in Res. 2009; PubMed Scopus Google Scholar) The of of these phosphatase-resistant LPA analogs was to that of also that intravenously administered not be a for that be in LPA was rapidly eliminated from the circulation. that the of of following intravenous administration was to that of were for active or analogs of LPA and lipids, including of lysophosphatidic acid Biophys. Acta. 2002; PubMed Scopus Google a of LPA A.J. Lynch and of inhibitors of autotaxin Med. Chem. 2010; PubMed Scopus Google and derivatives of LPA that the of of intravenously administered LPA and and lysophospholipids from the circulation of mice is at than and mechanisms that are of in situ and for of the lipid species following intravenous administration of a single bolus dose to are of from to in a new are of from to identify the for of intravenously administered the of in mice following a single bolus dose intravenous that more than of accumulated in the liver for a of LPA analogs with this that ligation of the hepatic blood the of removal of intravenously administered LPA from the circulation. of LPA in the liver was in the but not the that the of ligation on the of of intravenously administered was a of hepatic of the were that be to the induced by this and the vascular to the ligation these hepatic of using a liver In these the liver of a single bolus dose of LPA at first and this rapid of was a LPA range In these at in and of the acid of that be and not that mouse an LPA species to that of mouse than of the was in in this liver not administered lysophospholipids and analogs in the are of the lipids in the as a of the of these lipids in following a single 5 bolus are of from to in a new by perfused liver and isolated liver were and the of in the was as a fraction of the in the at association with and nonparenchymal liver cells a single bolus intravenous of with isolated and nonparenchymal liver cells in and are of The are of the lipids in the as a of the of these lipids in following a single 5 bolus are of from to identify which liver cells are for rapid uptake of LPA from the the of intravenously administered and in liver cell isolated rapid of using and to of cells from nonparenchymal cells and that was associated with the the cell fraction and not the of these liver cell to exogenously in that was more accumulated by isolated nonparenchymal cells than by isolated In that human liver cells and human vein cells more of exogenously provided than cells not These results suggest that nonparenchymal the cells blood rapid of circulating lysophospholipids by the liver. Our by and (11Albers H.M. Dong A. van Meeteren L.A. Egan D.A. Sunkara M. van Tilburg E.W. Schuurman K. van Tellingen O. Morris A.J. Smyth S.S. et al.Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation.Proc. Natl. Acad. Sci. USA. 2010; 107: 7257-7262Crossref PubMed Scopus (166) Google Scholar, J. A. K. E. L. T. A. M. O. S. et autotaxin inhibitor lysophosphatidic acid levels in plasma and the of 2010; PubMed Scopus Google Scholar) to that levels of major rodent plasma LPA species following pharmacological of the enzyme of this a for and LPA and for have been Y. Sunkara M. Morris A.J. Lynch of alkyl lysophosphatidic acid by Biophys. Res. PubMed Scopus Google to this to plasma levels were decreased following ATX this LPA species in plasma from mice on a levels of were the limit of and these lipids were not mouse plasma was in which levels of LPA were increased not species in human which is with M. P. J. G. Y. acid of lysophosphatidic acid and in plasma from with and Full Text PDF PubMed Scopus Google and have levels of in plasma from human as well as mice with or not be to levels are to ATX levels of major LPA species ATX is the mechanisms in removal of LPA from the circulation, and to the and of intravenously administered LPA in that the of of LPA from mouse plasma was more rapid than by A. C. Lynch Lipid phosphate 1 lysophosphatidic acid in J. 2009; PubMed Scopus Google Scholar, K. J. S. Y. C. T. as a of plasma sphingosine Res. 2008; PubMed Scopus Google which to to the administered LPA dose by using the plasma LPA be in whole blood results that is not in these rapid decreases in plasma LPA levels following ATX or intravenous LPA is with that of major vascular cell LPP3 in vascular smooth muscle or vascular cells not plasma LPA levels or the of of intravenously administered LPA 6Panchatcharam M. Miriyala S. Salous A. Wheeler J. Dong A. Mueller P. Sunkara M. Escalante-Alcalde D. Morris A.J. Smyth S.S. Lipid phosphate phosphatase 3 negatively regulates smooth muscle cell phenotypic modulation to limit intimal hyperplasia.Arterioscler. Thromb. Vasc. Biol. 2013; 33: 52-59Crossref PubMed Scopus (39) Google and The between and the in plasma LPA levels and of intravenously administered LPA in mice A. C. Lynch Lipid phosphate 1 lysophosphatidic acid in J. 2009; PubMed Scopus Google Scholar) to be Our results that intravenously administered LPA is accumulated in the liver. Studies using an isolated liver that ~90% of LPA accumulates in the liver the first pass. The of LPA, at at early times following intravenous administration, is in association with nonparenchymal cells of the which and In that the of in this fraction was associated with cells that be isolated by using a role for cells in rapid LPA uptake by the liver. These were by that this nonparenchymal cell fraction was more at in than were isolated and that of human vascular and liver cells also to this lipid in not with and metabolism of LPA by cells in has been J. van van of the active lysophosphatidic in Biophys. Acta. PubMed Scopus Google Scholar) and to be important in mechanisms of LPA signaling activation of the nuclear peroxisome proliferator γ receptor A. Y. Hama K. Aoki J. Arai H. et of an receptor for lysophosphatidic acid LPA is a PPARgamma Natl. Acad. Sci. USA. PubMed Scopus Google Scholar). A mechanism for by P. P. and sphingosine 1-phosphate in J. 21: PubMed Scopus Google but the of this to the of is not K. S. S. and of Biophys. Acta. 2009; PubMed Scopus Google Scholar). In LPA by cells was by of that this including which as a for and of the family not be to identify the it is that the of of intravenously administered LPA not the of the of LPA in the that at a fraction of plasma LPA is rapidly accumulated and in the liver. a mechanism for lysophospholipids from the plasma for hepatic of lipid metabolism or it in modulation of or LPA Our results also suggest an for LPA to associated with liver A role for the liver in and metabolism of circulating LPA is by that plasma LPA levels are increased in with and are strongly with the of liver dysfunction and N. H. K. Ohkawa R. Y. T. K. T. Arai M. M. et lysophosphatidic acid and autotaxin activity are increased in liver injury in in to Sci. PubMed Scopus Google Scholar, N. H. K. Ohkawa R. Y. Aoki J. Hama K. Okudaira S. M. T. et plasma lysophosphatidic acid and autotaxin levels are increased in PubMed Scopus Google Scholar). LPA also a role in of liver including and of in which is W. F. van van J. J. C. et al.Lysophosphatidic acid is a of 2010; Full Text Full Text PDF PubMed Scopus Google Scholar). in these may be to in circulating ATX levels W. F. van van J. J. C. et al.Lysophosphatidic acid is a of 2010; Full Text Full Text PDF PubMed Scopus Google it is that of the role of the liver in of circulating LPA to in plasma LPA study the that from the plasma leading to and metabolism in the liver to be as a mechanism that the bioavailability of LPA and These be an important determinant of the pharmacological of structural mimetics of these lipids as phosphonate and analogs of LPA that are to the and have potent LPA and in but studies that in be by rapid from the circulation G. at lysophosphatidic acid J. 2010; PubMed Scopus Google Scholar). to be a major of lipids that in the liver that signaling the in the of that be between and by sphingosine plasma and metabolism in cells and by to the or the in this to produce more bioactive therapeutics of the mechanisms for of these alkyl glycerol phosphate autotaxin phosphate ester lysophosphatidic acid lipid phosphate phosphatase 3 sphingosine 1-phosphate acid

References

31